Case Presentation {#S1}
=================

A 60-year-old man with type II diabetes was referred to our department due to blisters and erosions over the whole body. He had been treated with linagliptin, a dipeptidyl peptidase-IV inhibitor (DPP4i), for 1 year. Two months before the referral, he had suffered a deep, 7-cm-long dermal burn on the right forearm from a kitchen accident. Within 2 days after the burn, blisters had appeared on the right forearm, which were treated with a topical antibiotic ointment. However, multiple blisters and erosions gradually developed over the body over the course of 2 months. Physical examination revealed tense blisters and erosions of 5 mm to 2 cm in diameter with circumscribed erythematous lesions predominantly on the right forearm (Figure [1](#F1){ref-type="fig"}A). Blisters and erosions less than 5 mm in diameter without erythema were found on the face, the trunk, and the left leg (Figure [1](#F1){ref-type="fig"}B). Although BP180 NC16A chemiluminescent enzyme immunoassay (CLEIA) was negative (5.9 U/mL; normal, \<9.0 U/mL), histopathological examination of the blister showed sub-epidermal blister formation with some eosinophilic infiltration in the dermis (Figure [1](#F1){ref-type="fig"}C). Direct immunofluorescence showed linear deposition of IgG autoantibodies along the dermal--epidermal junction (Figure [1](#F1){ref-type="fig"}D), and 1 M NaCl-split skin indirect immunofluorescence revealed circulating IgG autoantibodies reacting with the epidermal side of the artificial blisters (not shown). Notably, enzyme-linked immunosorbent assay (ELISA) using full-length recombinant BP180 was positive (index value, 41.8; normal, \<4.64) ([@B1]). Based on these findings, the diagnosis of bullous pemphigoid (BP) was made. Linagliptin was withdrawn 2 days after the referral, and treatment with a topical steroid and minocycline at 100 mg/day was started. His skin lesions gradually improved, and ELISA with full-length recombinant BP180 became negative (index value, 1.03). Complete remission off therapy was achieved 4 months later (Figure [2](#F2){ref-type="fig"}). Although no DPP4i was re-administered, blisters appeared on the left forearm 16 months later, when he developed cellulitis on the right leg. The histopathology of the blister showed sub-epidermal blistering with scant eosinophilic infiltration in the dermis (not shown), which was consistent with BP. BP180 NC16A CLEIA was still negative (\<3 U/mL). Topical steroid, minocycline at 200 mg/day, and nicotinamide at 1,500 mg/day were initiated, and the lesions completely resolved 2 months later. At 2 months after the cessation of treatment, no recurrence was observed (Figure [2](#F2){ref-type="fig"}).

![**(A)** Tense blisters and erosions of less than 2 cm in diameter developed over the thermal burn scar on the right forearm. Circumscribed erythematous lesions were also found. **(B)** Small erosions of less than 5 mm in diameter were found on the trunk without erythema. **(C)** Histopathological examination of the blister shows sub-epidermal blistering with some eosinophilic infiltration in the dermis. Scale bar: 100 µm. **(D)** Direct immunofluorescence shows linear IgG autoantibody deposits at the basement membrane zone (arrowheads).](fimmu-09-00542-g001){#F1}

![Indices of the bullous pemphigoid (BP) disease area index scores ([@B2]) and enzyme-linked immunosorbent assay (ELISA) using full-length recombinant BP180 during the clinical course.](fimmu-09-00542-g002){#F2}

Introduction {#S2}
============

Bullous pemphigoid is a common autoimmune blistering disease in which autoantibodies target the hemidesmosomal components BP180 (also known as type XVII collagen) and/or BP230 at the dermal--epidermal junction ([@B3]). Clinically, tense blister formation associated with itchy urticarial erythema is typically observed in BP patients, and sub-epidermal blister formation with eosinophilic infiltration is histopathologically observed ([@B3]). Although the etiology of BP remains unclear, various factors, including radiotherapy, burns, ultraviolet (UV) exposure, trauma, surgical procedures, topical medications, and infections are known to trigger the onset of the disease ([@B4], [@B5]). Recently, emerging evidence reports that the use of DPP4i, which are widely used to treat patients with diabetes mellitus, increases the risk of BP onset ([@B6]--[@B9]).

Discussion {#S3}
==========

Herein, we report a case of BP in which a thermal burn triggered the onset of the disease. As shown in Table [1](#T1){ref-type="table"}, various BP-inducing physical factors, including radiation ([@B5], [@B10]--[@B18]), UV radiation ([@B5], [@B19]--[@B30]), surgical wounds ([@B5], [@B31]--[@B45]), ostomy ([@B31], [@B46]--[@B51]), burns ([@B5], [@B52]--[@B62]), skin grafts ([@B59], [@B63]--[@B67]), and other trauma ([@B5], [@B68]--[@B72]) have been reported in the English literature. Regarding thermal burns, 13 cases have been reported (Table [2](#T2){ref-type="table"}) ([@B5], [@B52]--[@B61]). Notably, in contrast to the present case, none of those 13 cases relapsed ([@B5], [@B52]--[@B61]) suggesting that the present case had a unique clinical course.

###### 

List of physical triggering factors for bullous pemphigoid.

  Triggering factor       No. of cases
  ----------------------- --------------
  Radiation               38
  UV                      37
   PUVA                   13
   UVB                    5
   Goeckerman             4
   PUVA and UVB           3
   UVA                    3
   Sunlight               2
   PUVA and sunlight      1
   PUVASOL                1
   Ingram                 1
   Unknown wavelength     4
  Surgical wound          22
  Ostomy                  19
   Colostomy              10
   Gastrostomy            5
   Ileostomy              2
   Urostomy               2
  Burn                    14
   Thermal burn           13
   Chemical burn          1
  Skin graft              6
  Other                   11
   Scratching             3
   Injury                 2
   Dye injection          1
   Mechanical trauma      1
   Insect bite            1
   Revascularization      1
   Photodynamic therapy   1
   Hernia                 1

*UV, ultraviolet; PUVA, psoralen-ultraviolet A; UVB, ultraviolet B; UVA, ultraviolet A; PUVASOL, psoralen-ultraviolet A and sunlight exposure*.

###### 

Overview of thermal burn-induced bullous pemphigoid (BP) cases.

  No.        Age   Sex   BP180       BP230   Diagnosis        Eruption      Delay after burn   Relapse         Reference
  ---------- ----- ----- ----------- ------- ---------------- ------------- ------------------ --------------- -------------------------------------
  1          80    M                         HE, DIF, IIF     Localized     2 weeks            Not mentioned   Jevtic and Grigoris ([@B52])
  2          69    M                         HE               Generalized   3 weeks            Not mentioned   Quartey-Papafio and Hudson ([@B53])
  3          75    F                         HE               Generalized   10 weeks           No              Balato et al. ([@B54])
  4          79    M                         HE. DIF, ssIIF   Localized     1 month            No              Vassileva et al. ([@B55])
  5          49    F                         HE, DIF          Localized     5 weeks            Not mentioned   Wagner et al. ([@B56])
  6          67    M                         HE, DIF          Generalized   8 months           No              Wagner et al. ([@B56])
  7          51    M     NC16A       (−)     HE, DIF, ssIIF   Generalized   6 weeks            No              Xu et al. ([@B57])
  8          68    F                         HE, DIF, ssIIF   Generalized   A few days         No              Korfitis et al. ([@B38])
  9          74    M                         HE, DIF          Generalized   2 weeks            Not mentioned   Bachmeyer et al. ([@B58])
  10         85    F     NC16A               HE, DIF          Localized     20 months          No              Neri et al. ([@B60])
  11         73    F                         HE, DIF          Generalized   6 weeks            Not mentioned   Damevska et al. ([@B60])
  12         89    F     (−)         (+)     HE, DIF, ssIIF   Localized     69 years           No              Morita et al. ([@B61])
  13         76    M     NC16A       (+)     HE, DIF          Generalized   A few hours        Not mentioned   Dǎnescu et al. ([@B5])
  Our case   60    M     Non-NC16A           HE, DIF, ssIIF   Generalized   2 days             Yes             

*M, male; F, female; HE, hematoxylin and eosin stain; DIF, direct immunofluorescence; IIF, indirect immunofluorescence; ssIIF, 1 M NaCl-split skin indirect immunofluorescence*.

Interestingly, linagliptin, which is a DPP4i, was adminis-tered to our case until the onset of BP. DPP4i-associated BP (DPP4i-BP) is a unique, recently reported subtype of BP that develops with the administration of DPP4i medications such as vildagliptin, sitagliptin, and linagliptin ([@B6]--[@B9]). DPP4i-BP tends to show scant erythema and low levels of autoantibodies targeting the NC16A domain of BP180 or the absence of such autoantibodies ([@B1], [@B73]). In our case, BP developed after 1 year of DPP4i administration, in which erythema was scantly observed and autoantibodies specifically targeted the non-NC16A domain of BP180. In addition, complete remission was achieved after the with-drawal of DPP4i and the initiation of treatment with topical steroid and systemic minocycline. Histopathologically, eosinophilic infiltration was not evident. These characteristics closely resembled those of the non-inflammatory type of DPP4i-BP ([@B1], [@B73]); therefore, DPP4i use may also be involved in the development of the disease. It should be noted that a recent study reported that 18% of DPP4i-BP cases relapsed even after the withdrawal of DPP4i ([@B7]). Although the immunohistopathological results were uncertain, the present case developed BP-like blisters when he suffered from cellulitis 16 months after complete remission, indicating that DPP4i was also associated with the BP onset in the present case.

The pathogenic mechanisms of the physical trigger for BP onset remain elusive. The physical factors cause tissue destruction that activates the inflammatory process, which may result in the observed auto-reactivity to basement membrane proteins, including BP180 ([@B5]). Alternatively, basement membrane proteins may be altered as a result of physical factors ([@B74]) resulting in immunogenicity with increased affinity to certain human leukocyte antigen (HLA) alleles ([@B75]). Notably, 86% of cases of the non-inflammatory type of DPP4i-BP carried HLA-DQB1\*03:01 ([@B73]). Although the HLA allele was not examined, it is likely that the present case had a genetic propensity to the breakdown of self-tolerance to BP180.

Concluding Remarks {#S4}
==================

In conclusion, we reported a case of BP induced by a thermal burn. Interestingly, the patient received DPP4i and showed the typical clinical, histopathological, and immunological characteristics of the non-inflammatory type of DPP4i-BP. Although the pathogenesis of thermal burn-induced BP and DPP4i-BP remains uncertain, BP may occur due to various triggering factors.
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